Lundbeck Inc. Soars on Phase 3 Study Results for Experimental Antidepressant
Published: May 16, 2012
H. Lundbeck A/S (LUN) rose the most in six months after saying an experimental antidepressant showed statistically significant results in three late-stage studies that will support regulatory filings in the U.S. and Europe. The shares gained 8.8 percent, the biggest gain since Nov. 11, to 118.60 kroner in Copenhagen, where the company is based. The drugmaker is developing the product with Japanese partner Takeda Pharmaceutical Co. (4502) Data from the three studies showed LU AA21004 reduced depression symptoms in a dose range from 10 milligrams to 20 milligrams, compared with placebo, the company said in a statement today.